Australia Fertility Services Market Size, Share, Report 2025-2033

Market Overview

The Australia fertility services market size reached USD 922.00 Million in 2024 and is expected to grow to USD 2,697.77 Million by 2033. The market is projected to expand at a CAGR of 12.67% during the forecast period of 2025-2033. Growth is driven by delayed parenthood, increased diagnoses of infertility, heightened awareness, technological advances such as genetic screening, and growing adoption of fertility preservation. Expanding accessibility and supportive healthcare policies are further fueling market momentum. For more details, visit the market page: Australia Fertility Services Market https://www.imarcgroup.com/australia-fertility-services-market

How AI is Reshaping the Future of Australia Fertility Services Market

• AI-powered genetic screening is enhancing diagnostic precision, enabling earlier and more accurate identification of infertility causes.
• Integration of AI in treatment personalization improves IVF success rates through optimized hormone therapy regimes and embryo selection.
• AI-driven predictive analytics supports fertility preservation strategies by forecasting individual patient reproductive potential.
• Government initiatives, like the expansion of Pharmaceutical Benefits Scheme, are increasing access to advanced AI-based contraceptives and IVF medications.
• AI-enabled counseling tools are enhancing emotional and psychological support for patients, as seen in Queensland's integrated fertility and counselling programs.
• The rollout of AI-managed public fertility programs, such as Victoria’s free public fertility initiative, is accelerating patient reach and resource efficiency.

Grab a sample PDF of this report: https://www.imarcgroup.com/australia-fertility-services-market/requestsample

Market Growth Factors

The rising demand due to delayed parenthood and an increasing prevalence of infertility diagnosis is expected to drive the growth of the market. The market growth is driven by changing social norms regarding the timing of parenthood and increasing infertility diagnosis among the population. Finally, improvements in diagnosis and treatment using genetic screening and more personalized therapies have improved treatment success, and have also raised awareness and encouraged families to access fertility services earlier rather than waiting for failed attempts at conception.

From an open market standpoint, increased access to reproductive healthcare services by providing affordable services and care is driving market growth. Increased availability of advanced contraception, targeted treatment for endometriosis, and LH for IVF are altering patient care. The government's inclusion of medications such as Slinda, Ryeqo, and Pergoveris in the Pharmaceutical Benefits Scheme can help make fertility services more affordable and accessible across the country.

Policies, such as in Queensland, are also in place to address equality of access to fertility services and thorough patient-centered support. The government has supported the subsidization of assisted reproductive technology in public hospitals. This reduces the financial burden on patients with serious illness such as cancer. The policy also provides for counseling to help with emotional or psychological issues. It is one of the first integrated reproductive health policies, greatly expanding the patient base to meet demand.

Market Segmentation

Cause of Infertility Insights:

• Male Infertility
• Female Infertility

Procedure Insights:

• In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI)
• Surrogacy
• In Vitro Fertilization Without Intracytoplasmic Sperm Injection (IVF without ICSI)
• Intrauterine Insemination (IUI)
• Others

Service Insights:

• Fresh Non-Donor
• Frozen Non-Donor
• Egg and Embryo Banking
• Fresh Donor
• Frozen Donor

End User Insights:

• Fertility Clinics
• Hospitals
• Surgical Centers
• Clinical Research Institutes
• Cryobanks

Regional Insights:

• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Key Players

• Not provided in source.

Recent Development & News

• April 2025: The Victorian government reached a milestone with over 150 babies born through Australia's first free public fertility program, including operations via satellite clinics and support from the first public egg and sperm bank at the Royal Women’s Hospital, reflecting significant progress in public fertility healthcare access.
• March 2025: The Australian Government expanded Pharmaceutical Benefits Scheme listings to enhance accessibility to contraception, endometriosis treatments, and IVF medications such as Slinda, Ryeqo, and Pergoveris, supporting broader patient reach and affordability.
• March 2024: Queensland introduced a public funding package to subsidize assisted reproductive technology in public hospitals for residents affected by serious illnesses like cancer, complemented by counseling services to address treatment-related emotional challenges, enhancing equitable fertility care access.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

https://www.imarcgroup.com/request?type=report&id=42069&flag=F

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302